Enveric Biosciences, Inc. (ENVB)

0.8610 -0.0196 (-2.23%) At close: 04:00PM EDT

Enveric Biosciences, Inc.

4851 Tamiami Trail N
Suite 200
Naples, FL 34103
United States
239 302 1707
https://www.enveric.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 7

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Joseph Edward Tucker Ph.D.	CEO & Director	450.79k	N/A	1969
Dr. Peter J. Facchini Ph.D.	Chief Innovation Officer	233.27k	N/A	1964

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Corporate governance

Enveric Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.